LONG-TERM OUTCOMES OF TACROLIMUS VS. ANTI-TUMOR NECROSIS FACTOR AGENTS IN THE TREATMENT FOR ULCERATIVE COLITIS: A MULTI-INSTITUTIONAL, PROPENSITY SCORE MATCHING COMPARATIVE EFFICACY STUDY

被引：0
|
作者：
Yamada, Takuya
Yoshihara, Takeo
Amano, Takahiro
Sakakibara, Yuko
Osugi, Naoto
Ishii, Shuji
Egawa, Satoshi
Araki, Manabu
Arimoto, Yuki
Nakahara, Masanori
Murayama, Yoko
Kobayashi, Ichizo
Kinoshita, Kazuo
Ogawa, Hiroyuki
Hiyama, Satoshi
Shibukawa, Narihiro
Komori, Masato
Okuda, Yorihide
Kizu, Takashi
Shinzaki, Shinichiro
Iijima, Hideki
Tsujii, Yoshiki
Hayashi, Yoshito
Takehara, Tetsuo
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
EP143
引用
收藏
页码：S1217 / S1217
页数：1
相关论文
共 27 条
  • [21] ILEOCECAL RESECTION FOR RECENTLY DIAGNOSED ILEOCECAL CROHN'S DISEASE IS ASSOCIATED WITH IMPROVED LONG-TERM OUTCOMES COMPARED TO ANTI-TUMOR NECROSIS FACTOR THERAPY: A POPULATION-BASED STUDY
    Agrawal, Manasi
    Ebert, Anthony C.
    Poulsen, Gry
    Ungaro, Ryan C.
    Faye, Adam S.
    Jess, Tine
    Colombel, Jean Frederic
    Allin, Kristine H.
    GASTROENTEROLOGY, 2023, 164 (06) : S4 - S4
  • [22] LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS WITH AND WITHOUT PRIOR ANTI-TUMOR NECROSIS FACTOR EXPOSURE: 96-WEEK OUTCOMES FROM THE RAPID-PSA TRIAL
    Mease, P. J.
    Fleischmann, R.
    Wollenhaupt, J.
    Deodhar, A.
    Gladman, D.
    Hoepken, B.
    Peterson, L.
    van der Heijde, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 90 - 90
  • [23] Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
    Song, Joo Hye
    Kang, Eun Ae
    Park, Soo-Kyung
    Hong, Sung Noh
    Kim, You Sun
    Bang, Ki Bae
    Kim, Kyeong Ok
    Lee, Hong Sub
    Kang, Sang-Bum
    Shin, Seung Yong
    Song, Eun Mi
    Im, Jong Pil
    Choi, Chang Hwan
    GUT AND LIVER, 2021, 15 (05) : 752 - 762
  • [24] Ileocecal resection for recently diagnosed ileocecal Crohn's disease is associated with improved long-term outcomes compared to anti-tumor necrosis factor therapy: a population-based study.
    Agrawal, M.
    Ebert, A.
    Poulsen, G.
    Ungaro, R.
    Faye, A.
    Jess, T.
    Colombel, J. F.
    Allin, K.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I16 - I17
  • [25] Long-term outcomes of endoscopic balloon dilation for intestinal strictures in patients with Crohn's disease during maintenance treatment with anti-tumor necrosis factor alpha antibodies (vol 34, pg 517, 2022)
    Takeda, T.
    Kishi, M.
    Takatsu, N.
    DIGESTIVE ENDOSCOPY, 2022, 34 (06) : 1274 - 1274
  • [26] Long-term Outcomes and Risk Factors for Reoperation After Surgical Treatment for Gastrointestinal Crohn Disease According to Anti-tumor Necrosis Factor-alpha Antibody Use: 35 Years of Experience at a Single Institute in Korea
    Lee, Sang Mok
    Han, Eon Chul
    Ryoo, Seung-Bum
    Oh, Heung-Kwon
    Choe, Eun Kyung
    Moon, Sang Hui
    Kim, Joo Sung
    Jung, Hyun Chae
    Park, Kyu Joo
    ANNALS OF COLOPROCTOLOGY, 2015, 31 (04) : 144 - 152
  • [27] Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: The long-term extension (LTE) of the attain trial
    Dougados, M.
    Schiff, M.
    Luggen, M.
    Becker, J. C.
    Aranda, R.
    Li, T.
    McCann, T.
    Schmidely, N.
    LeBars, M.
    Sibilia, J.
    Genovese, M. C.
    RHEUMATOLOGY, 2007, 46 : I99 - I99
123